ANT-GROUP/KOMINFO
24.5.2022 07:33:06 CEST | Business Wire | Press release
The Ministry of Communication and Informatics (“Kominfo”) today announced its partnership with fintech training platform 10x1000 Tech for Inclusion (“10x1000”) to recruit local talents to enroll in 10x1000’s “Flex” Fintech Foundation Program.
This partnership forms part of Kominfo’s Digital Entrepreneurship Academy (“DEA”) program, which aims to prepare and nurture talents to accelerate digital transformation in the field of entrepreneurship and to improve the digital economy, with a target of 60,000 people being trained in 2022.
“The Ministry of Communication and Informatics appreciates the collaboration with 10x1000 to carry out digital entrepreneurship training through the DEA program. The results of the program are expected to improve the quality of Micro, Small and Medium Enterprises (MSMEs) and promote the digital economy in Indonesia,” said Hary Budiarto, Head of HR & Research Agency, Ministry of Communication and Informatics (Kominfo).
With the vision to train 1,000 emerging talents and tech leaders each year for ten years, 10x1000 saw a total of 1,067 learners from 66 countries and regions complete its “Flex” Fintech Foundation Program and Fintech Leadership Program in 2021. Of which, more than 150 learners were from Indonesia, making the country the second largest globally in terms of learner intake.
“We are deeply encouraged by the overwhelming responses from Indonesia last year, and excited to partner with Kominfo to further expand the reach in Indonesia and make 'Flex' available to more local entrepreneurs and professionals to enhance their fintech mindset, knowledge and skills to better allow them to drive digital economic growth,” said Mr. Jason Pau, Program Lead of 10x1000. “Technology pervades nearly every aspect of our lives, and we hope this partnership will help Indonesia bridge its digital skills gap while empowering and improving the lives of local communities. Together with Kominfo and other local partners, we look forward to contributing more to Indonesia’s digital development goals.”
“The Coordinating Ministry of Human Development and Culture also expresses our appreciation to Kominfo for taking the initiative in driving such fintech training collaborations for women entrepreneurs and MSMEs (an initiative of the Ministry) with 10x1000,” said Femmy Eka Kartika Putri, Deputy of Coordination for Quality Improvement of Children, Women and Youth, Coordinating Ministry for Human Development and Culture (Kemenko PMK). “At least 60% of MSMEs in Indonesia are managed by women and contribute at least 61.07% of the country's GDP. With the 'Flex' Fintech Foundation Program by 10x1000 Tech for Inclusion, it will encourage women entrepreneurs to further enhance their businesses through digital technology. The training program is expected to help women entrepreneurs and MSMEs overcome challenges such as limited access to entrepreneurship and understanding of digital technology, as well as difficulties in obtaining access to capital.”
Registration for the “Flex” Fintech Foundation Program is now open through Kominfo’s Digital Entrepreneurship Academy website here . The first batch of training is slated to start on 6 June. Local fintech and banking associations will support the initiative by inviting their members to enroll the program as well, including the Indonesia Fintech Association (AFTECH), Indonesian Joint Funding Fintech Association (AFPI), Indonesian Sharia Fintech Association (AFSI), Indonesian Crowdfunding Service Association (ALUDI), Indonesian Blockchain Association (ABI), Association of Indonesia Shariah Banks (ASBISINDO), Indonesian Sharia Insurance Association (AASI), Association of National Commercial Banks (PERBANAS), and Indonesian E-commerce Association (idEA).
The partnership with Kominfo is the latest effort by 10x1000 to deepen its collaborations with partners worldwide. Globally, 10x1000 has forged partnerships with the IFC, United Nations Economic Commission for Africa, UN World Food Programme, SME Finance Forum Managed by the IFC, Dubai International Financial Centre, MDEC, KPMG and fintech associations from Hong Kong, Singapore, Malaysia, MENA, the Philippines and Thailand to recruit learners and grow the community.
About KOMINFO
Ministry of Communication and Informatics is responsible to carrying out government affairs in the field of communication and information technology to assist the President in administering government. Its main task and function to formulate national policies, implementation policies, and technical policies in the field of communication and informatics which include post, telecommunications, broadcasting, information and communication technology, multimedia services and information dissemination. The Ministry of Communications and Informatics is led by a Minister of Communication and Information (Menkominfo) who since October 23, 2019 has been held by Johnny Gerard Plate.
About DEA
The Digital Entrepreneurship Academy (DEA) is a program from the Ministry of Communication and Information that aims to prepare digital talent to accelerate Indonesia digital transformation in the field of digital entrepreneurship in order to improve the digital economy, with a target of 60,000 people being trained in 2022. The targets of this program include creating new digital entrepreneurs, upskilling advanced digital entrepreneurs, and developing digital entrepreneurship in inclusive villages. More details of the program please visit https://komin.fo/DEA
.
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523006072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
